

### **Projectathon Day 3**

**Programming Slides** 


March 23, 2022

### **Agenda**

#	Activity	Objectives	Time (EST)				
1	Welcome	<ul><li>Provide update on Day 1&amp;2</li><li>Outline the day's programming</li></ul>	10:45 – 11:00				
2	FHIR Content Data Model – Facilitated Roundtable	Discuss implementer experience with PS-CA and CA:FeX including mapping native application data to the new FHIR profiles	11:00 – 11:45				
3	Supporting Profiles for PS-CA – Facilitated Roundtable	Successful exchange of Patient Summaries is likely to depend on a number of supporting services – explore some examples and learn future needs	12:00 – 12:45				
	Break						
4	Approaches to document management – Facilitated Roundtable	Discuss implementer experiences and approaches available for handling patient's longitudinal record, specifically focused on document format	1:30 – 2:15				
5	Clinical Workflow – Facilitated Roundtable	<ul> <li>Share outcomes of previous clinician sessions</li> <li>Discuss vendor experiences with supporting clinical workflows, specifically related to Patient Summaries</li> </ul>	2:30 – 3:15				
6	Wrap-Up	<ul><li>Discuss overall key learnings from the event</li><li>Discuss next steps</li></ul>	3:30 – 4:00				




### **Review Cycles**






### **Projectathon Focus: Patient Summary PS-CA**

The pan-Canadian Patient Summary specification (PS-CA) is a level 2 specification







### **Projectathon Focus – Day 1&2**

Profiles that are subject to testing based on vendor registration include CA:FeX, MHD, XDS,

IUA, ATNA, CT, and PIX.

	Allscripts	CERNER	Juniper	SmileCDR	EPIC	Infoway*
Allscripts		IUA		CA:FeX		
CERNER	IUA		IUA	CAIFOV	VDS	CA:FeX
CERINER	CA:FeX		CA:FeX	CA:FeX	XDS	MHD
Juniper		CA:FeX		CA:FeX		CA:FeX
Julipei		MHD		CA.I EX		MHD
SmileCDR	IUA	IUA	IUA			
EPIC		XDS				
Infoway*		CA:FeX	CA:FeX			
iiiioway		MHD	MHD			



### Part 1: March 21 & 22: Peer to Peer Testing

In this phase of testing, participating vendors can work with partners to execute the test steps for the desired profiles

<sup>\*</sup>Infoway will provide CA:FeX and MHD simulators in case vendors cannot find a partner, or want to do multiple tests





#### Pan-Canadian Projectathon, March 2022

**Day 2 Summary** 



#### Day 2 Projectathon Dashboard - Overall Test Execution Summary

		Test Instance Execution Summary				
	# of Tests Verified	# of Tests Partially Verified	# of Tests In Progress	Total		
CA:FeX	8	-	3	11		
MHD	4	1	10	15		
XDS.b	-	-	12	12		
ATNA	4	1	1	6		
СТ	-	-	1	1		
PIXV3	1	-	-	1		

<sup>\*</sup>Source: Gazelle Pan-Canadian-Projectathon-2022 as of 4:30 PM EST 3/22/2022



# FHIR Content Data Model

**Facilitated Roundtable** 



#### **Content Data Model: PS-CA Building Blocks**

Patient Summary-CA: Data Domains of Interest by Canadian Jurisdiction and Release

	IPS-UV		PS- CA	AB	BC	МВ	NL	ON	SK	Release 1	Release 2+
ler	Subject		Subject								+
	Author	Header	Author								+
Head	Attester		Attester								+
	Custodian		Custodian								+
p	Medication Summary		Medication Summary								+
Required	Allergies and Intolerance:		Allergies and Intolerances								+
Rei	Problem List	papu	Problem List								+
pi	Immunizations	Recommen	Immunizations								+
ende	History of Procedures		History of Procedures								+
ommo	Medical Devices		Medical Devices								
Rec	Diagnostic Results		Diagnostic Results								
	Vital Signs		Vital Signs								+
	Past history of Illness		Past History of Illness								+
a	Social History		Social History								+
tion	Advance Directives	Option	Advance Directives								
op	Pregnancy		Pregnancy								
	Functional Status		Functional Status								
	Plan of Care		Plan of Care								
		EXT	Extension(s) Family History								

#### Notes

PRelease 2: Includes the data domains from Release 1, including Release 2 roadmap items, and the highlighted data domains that were not included in Release 1.



<sup>·</sup> Coordinating table discussion for October 7th: Approval to move Medical Devices and Diagnostic Results to Release 2.

Release 1: Includes the highlighted data domains.

#### **Content Data Model**



**FHIR Profiles:** What challenges did you encounter with the existing data model constraints (e.g., MS flags, codeableConcept expectations, composition sections)?

How and where did these show up in the rendered PS-CA/outputs of testing?



**Terminology:** What challenges & opportunities does the proposed terminology present to vendor implementers?

 How can we make pan-Canadian terminology more accessible to incorporate into test & production systems?



**Release Cadence:** How much lead time do vendors need to incorporate new specification releases into their systems?

 What are the maturity indicators that guide vendor decision to adopt a newer release of the specification?



### **Exchange Interface – Actors/Transactions**

PS-CA Actor	Required IHE Supporting Profiles (Actors)	Optional IHE Supporting Profiles (Actors)					
Option 1: Document Repository using MHD							
PS-CA Producer	MHD Document Source	IUA, SVCM PDQm (Consumer)					
Document Repository	MHD Document Recipient						
Central Infrastructure		PMIR (Patient Identity Registry)					
PS-CA Consumer	MHD Document Consumer	IUA, SVCM PDQm (Consumer) CA:FMT (Client)					
	Option 2: FHIR HIE						
PS-CA Producer	CA:FeX (Data Source)	IUA, SVCM PDQm (Consumer)					
Document Repository	CA:FeX (Data Recipient, Data Responder)						
Central Infrastructure		PMIR (Patient Identity Registry)					
PS-CA Consumer	CA:FeX (Data Consumer)	IUA, SVCM PDQm (Consumer) CA:FMT (Client)					

Transactions by Option				
Option 1 Transactions				
Save PS-CA to Document Repository Provide Document Bundle [ITI-65]				
Retrieve PS-CA from Document Repository  Find Document Lists [ITI-66]  Find Document References [ITI-67]  Retrieve Document [ITI-68]				
Option 2 Transactions				
Save PS-CA to Document Repository  • Submit Data [CA:FeX-1]				
Retrieve PS-CA from Document Repository • Search Data [CA:FeX-2A]				

• Retrieve Data [CA:FeX-3A]

#### **Exchange Interface – Round Table**

#### **Specification Clarity**

Clear expectations for the following:

- Required and optional Profiles, Actors and Transactions
- Supported and required Query parameters
- Responses content (e.g., search results), error codes
- Other transaction content (expected actions, semantics, etc.)

#### **Transaction Patterns**

- Specified patterns align with existing/previously planned product capabilities
- What factors driving selection of implementation options?
- Is there a need for a different pattern?

#### Implementation support

• Additional specification content and collateral? Supporting services? Reference architecture? Reference Implementation? Training? Other?




#### Open Q&A



## Any Questions from the Audience?


### **Appendix: Screenshot of Rendered PS-CA**



# **Supporting Profiles** for PS-CA


**Facilitated Roundtable** 

#### Reference Architecture







### OAuth 2.1 refresher (authorization code flow)



#### **IUA - Internet User Authorization**




#### **IUA** and **SMART** on FHIR



### Internet User Authorization (IUA)


- IUA and its role in supporting access controls
- Experience in blending Access tokens with the FHIR APIs
- Experience in using IUA with SMART on FHIR demo
- What do the real world environments looking like?
- International deployments, support for CA:FeX, MHD, what supporting services help facilitate FHIR exchanges?





### Patient Identification (PIXm/PDQm)

- International experience in patient identification
- Are services such as PIX/PDQ employed in the realms you operate in?






# **Approaches to Document Management**

**Facilitated Roundtable** 

#### A Heterogeneous Ecosystem and the Patient Record



# The complexity grows as new implementation patterns emerge.

With such a heterogeneous health ecosystem, it may not be realistic for all systems to converge on a single way of doing things.

Vendors cannot change established implementations overnight. So how do we manage this long-term transition?



### What is your lived experience?

#### **Topic 1: FHIR-Based Integrations**

Are there examples of a health ecosystem that is largely based on pure FHIR-based integrations? What are the patterns that you see emerging? How are you managing the wide variety of documents?

#### **Topic 2: Heterogeneous Gateways**

How should the heterogeneity of the ecosystem be dealt with among members? What are some of the approaches to establishing mixed gateways (e.g., MHD and FHIR-based vendors)?

#### **Topic 3: Transitioning to FHIR**

How does the transition to FHIR affect your business? What are some of the key considerations that standard developers and PTs should be aware of during this transition period?

#### **Topic 4: Understanding the Choices**

In regions, such as the US and Europe, XDS has become the backbone for document exchange. How do these health ecosystems evolve with emerging implementation patterns? Are there gaps or key benefits we may be giving up if vendors move away from XDS in the future?



### How do we make the right choices?

#### **Topic 5: Making Informed Decisions**

How will we help information custodians make the appropriate choice? Is it as simple as separating the greenfield opportunities from the established ecosystems?




# Heterogeneity:

**Exchange Standards** 

### Standards are evolving to manage FHIR adoption

The ONC understands the need to manage the emerging adoption of FHIR and adapt exchange standards appropriately – they will first start with the payload.

Stage 1: Enabling FHIR Content Exchange






### Standards are evolving to manage FHIR adoption


Once content of both old and new formats can be managed, the ONC will shift its attention toward FHIR exchanges within the network and the appropriate services to bridge the gap.

Stage 2: Network-Facilitated FHIR Exchange



### Standards are evolving to manage FHIR adoption

The ONC is in favour of optionality with a long-term vision of providing legacy IHE exchange patterns in addition to the appropriate services and infrastructure to broker and facilitate new, FHIR exchanges across networks.



### **Clinical Workflow**

**Facilitated Roundtable** 

### **Objectives**

- 1. Share outcomes of previous pan-Canadian Patient Summary clinician sessions
- 2. Discuss vendor experiences and near-term opportunities to improve integration of Patient Summaries into existing clinical workflows



### Pan-Canadian Patient Summary (PS-CA)



An electronic Patient Summary for use at the **point of care** comprised of, at minimum, the required elements of the Patient Summary-CA data set and specifications.

The PS-CA is a health record extract, at a snapshot in time, comprised of a standardized collection of clinical and contextual information (retrospective, concurrent, prospective), including the minimum necessary and sufficient data to inform a patient's treatment at the point of care.

The Patient Summary is condition-independent and specialty-agnostic, irrespective of the condition of the patient or the treatment sought or specialty of the provider delivering care.

#### **Proposed Content:**



Release Roadmap

Release 1 Release 2



### Discussion topics from previous clinician sessions























### Impacts to Clinical Workflows & Approach to Terminology





#### WHAT WE ASKED THE CLINICIANS:

- What impacts to clinical workflows must considered when either producing or consuming a Patient Summary?
- What are the qualities we should be looking for in "low-hanging fruit" opportunities to align terminology?

#### WHAT WE HEARD FROM THE CLINICIANS:

The Patient Summary must:

- be seamlessly integrated into existing workflows and not create additional administrative burden.
- focus on **what will make the most clinical difference**. Challenge to "get it right" with free-text and coded values locally before introducing cross-border care.
- not add additional data entry and complexity of entering coded data (e.g., consider options such as artificial
  intelligence, important that a clinician can choose to see the free-text, not just a coded value)
- find a balance between keeping the PS relevant / up to date but not onerous for the primary physician
- consider Patient access and ability to contribute to their own Patient Summary

#### Policy, Regulations & Persistence of the Patient Summary





#### WHAT WE ASKED THE CLINICIANS:

- What are important considerations for Policy and Regulations of the Patient Summary that clinicians care about?
- Would clinicians trust the data of a system that has multiple Patient Summaries for each provider that is responsible for that patient?

#### WHAT WE HEARD FROM THE CLINICIANS:

The Patient Summary should:

- be **trustworthy**: Clinicians should be able to trust that the system creating the Patient Summary will apply the necessary guidelines according to their jurisdictional policies and regulations (e.g., privacy legislation, regulations from physician colleges, regulatory frameworks from ministries) ensuring that the clinician does not have to figure out all the rules and regulations and that physician obligation/liability, with respect to updates, is clearly understood.
- be one summary of information that is **simple and easy to scan**. It should not contain multiple layers of information.
- consider option to **identify new /changed information** (e.g., provide a flag for new information / differences between Patient Summaries, identified by date.
- contain **information from more than one source of truth**, ensuring the most up-to-date information
- consider if a document may **persist x5** (i.e., from five different people) or **no document** exists and only the data is accessible at the point of care when needed.

#### **Round-table Discussion: Vendor Perspective**



#### **Impacts to Clinical Workflows**

- What experience have the vendors had with producing or consuming a Patient Summary?
- What are some near-term opportunities to improve integration of Patient Summaries into existing clinical workflows?
- How does the market manage patient consent and how can it be applied to the creation and distribution of Patient Summaries?





# Wrap Up

### **Projectathon Days 1 & 2 Debrief**





Purpose: To test the PS-CA and CA:FeX Specifications

#### **Key Achievements:**

- Kicked-off first pan-Canadian Projectathon to test and improve Patient Summary Interoperability Specifications (PS-CA & CA:FeX)
- Participating vendors performed several pre-Projectathon, No-Peer Tests and Peer-to-Peer tests
- Observed engagement from 35+ participants

#### Conclusion:

- The Projectathon has proven that the PS-CA allows for generation of a FHIR-based PS-CA document
- The IHE methodology and pan-Canadian Projectathons are effective tools to support testing and facilitate ecosystem collaboration

Total Profiles Tested	Total No-Peer Tests Verified	Total Peer-to- Peer Tested Verified	# of Items for Consideration for PS-CA Specification
6	14	14	TBD



#### **Vendor Feedback**

What were some key learnings from Day 1 & 2?

#### **General Feedback**

 Do you have comments or feedback on implementing the specifications during the Projectathon? How did you find using Gazelle and the IHE Methodology?

#### **Testing Environment and Process**

 Understanding that more preparation time is needed, would you be interested in future events?



### **Next Steps**

Immediate Term	Long-Term
<ul> <li>Feedback from Day 3 sessions (Survey Monkey)</li> <li>Closing open review and dispositioning of feedback from PS-CA v 0.3 and CA:FeX v0.2</li> <li>Governance bodies reviews and approvals</li> <li>Publishing PS-CA v1.0 TI and CA:FeX v1.0 DSTU - May</li> </ul>	<ul> <li>Develop an interoperability roadmap</li> <li>Support implementations of the published specification</li> <li>Evolve the specifications</li> <li>Refine the Interoperability Program, including governance, process and methodology (Connectathons, etc)</li> </ul>



#### **Questions and Feedback**



Any questions we did not get to today can be directed to the following individuals:

Attila Farkas at <a href="mailto:afarkas@infoway-inforoute.ca">afarkas@infoway-inforoute.ca</a>

Michelle Cerqua at <a href="mailto:mcerqua@infoway-inforoute.ca">mcerqua@infoway-inforoute.ca</a>



Recordings from Day 3 will be posted in the Patient Summary Working Group <a href="https://infocentral.infoway-inforoute.ca/en/collaboration/wg/patient-summaries">https://infocentral.infoway-inforoute.ca/en/collaboration/wg/patient-summaries</a>



We want your feedback! Please share your feedback with us by **Monday, March 28** by completing this short, 5-minute survey: <a href="https://www.surveymonkey.com/r/CZFZV38">https://www.surveymonkey.com/r/CZFZV38</a>



## Thank you!

**VISIT OUR WEBSITE** 

infoway-inforoute.ca

**VISIT OUR SURVEY WEBSITE** 

insights.infoway-inforoute.ca/

LET'S CONNECT ON LINKEDIN

linkedin.com/company/canada-health-infoway/

**LET'S CONNECT ON TWITTER** 

@infoway